Izon Science Introduces qEV PurePath for Industrial-Scale EV Isolation Solutions

exosomes

Izon Science has announced the arrival of qEV PurePath – a versatile and cooperative service designed to bolster efforts in EV therapeutics and diagnostics.

The immense therapeutic and diagnostic potential of extracellular vesicles (EVs) has been progressively acknowledged, inching EV-based tests and products closer to their market deployment. Yet, a critical challenge remains: current EV isolation processes lack the necessary scalability. Crafting efficient and scalable workflows is an endeavor that requires significant resources, proving to be a daunting task for both nascent start-ups and established corporations.

Through Izon’s global collaborations, significant strides have been made in advancing the technology and expertise required for EV isolation. This culminated in the creation of qEV PurePath, a highly customizable service that stands to dramatically enhance the scale of EV isolation.

qEV PurePath: Custom-Designed to Expedite and Scale EV Isolation Workflows

The qEV PurePath service offers a comprehensive solution, incorporating the conceptualization, fine-tuning, testing, and execution of a tailored, high-throughput EV isolation workflow. By doing so, Izon aims to simplify the process of refining EV isolation, enabling researchers to dedicate more resources to developing their EV diagnostic tests or therapeutics. In an industry where hefty R&D costs are typical, Izon’s service may reduce both time and financial pressures, propelling diagnostic and therapeutic companies towards their market objectives more efficiently.

At the heart of the qEV PurePath service is Izon’s deep knowledge of EV isolation, enabling high levels of customization. The qEV size exclusion column technology is fundamental to the qEV PurePath workflow, as is their experience in working with a broad range of research groups. Acknowledging the diverse needs of their clients, Izon is taking two distinct approaches with qEV technology to cater to the unique requirements of EV therapeutics and diagnostics.

qEV PurePath for Therapeutics

The potential of EV therapeutics largely depends on the capability to scale – specifically, the scale of sample volume. Transforming copious amounts of cell culture media into a consistent, concentrated, and pure EV isolate is a massive undertaking. Additionally, sterility is paramount, making automated processing in a sterile environment a necessity for safe production.

Izon’s exploration of a solution started with a collaboration with a company focused on the functional properties of EVs. To meet their need for large-scale separation, Izon developed a qEV column that is over 400 times larger than the widely used qEVoriginal columns. As these substantial columns must be custom-designed for each client and built into wider workflows, qEV PurePath for Therapeutics was conceived.

Figure 1. An exemplar, conceptual qEV PurePath workflow for therapeutics. Step 1 is clarification, which for automated systems is most likely to be in the form of serial filtration steps to eliminate larger contaminating particles. Next up is sample concentration, for which Izon recommends their tried and tested tangential flow filtration solution. After concentration, EVs are isolated in the form of a fully customised size exclusion chromatography column based upon qEV technology. Quality control steps follow, where particle size, concentration and zeta potential can be measured using Tunable Resistive Pulse Sensing, followed by assessments of potency and reproducibility (using assays built in partnership). Finally, the well-characterised and pure product is stored for use. Pink = EVs; blue = protein; purple = large contaminants.

qEV PurePath for Diagnostics

The needs for EV diagnostics substantially differ from those of therapeutics. For diagnostics, scalability is measured by the number of tests that can be performed within a specific timeframe. With this in mind, Izon has leveraged insights from collaborations with diagnostic companies, and is now positioned to devise workflows that emphasize test scalability and signal-to-noise ratio, through qEV PurePath for Diagnostics.

To substantially enhance the throughput of EV isolation for diagnostics, Izon is developing two novel instruments; one of which is expected to become available later this year.

Figure 2. An exemplar, conceptual workflow for qEV PurePath for diagnostics. The first step is clarification to remove large contaminating particles such as cells and cell fragments. For diagnostics, this will most likely be in the form of filtration. Following filtration, qEV isolation at scale will occur, with multiple samples isolated simultaneously. Following isolation, EVs will be concentrated. Finally, your diagnostic test can be allowed to shine. Pink = EVs; blue = protein; purple = large contaminants.

 The qEV PurePath to Clinical Success

With the unveiling of the two distinct branches of qEV PurePath, growing companies and driven research groups can accelerate the intricate and resource-demanding task of optimizing EV isolation for diagnostics or therapeutics. Izon’s expertise extends beyond the well-known qEV columns or Tunable Resistive Pulse Sensing instruments, and the valuable insights they’ve gleaned can significantly quicken the transition of diagnostic and therapeutic tests into clinical application. Izon’s qEV PurePath represents a significant stride in the EV isolation field, with the respective services a testament to ongoing scientific endeavors and the relentless pursuit for efficient and scalable solutions in the rapidly-evolving landscape of EV therapeutics and diagnostics.

exosmes

Leave a Reply

Your email address will not be published. Required fields are marked *

*